309 related articles for article (PubMed ID: 29460635)
1. Nivolumab in the treatment of advanced renal cell carcinoma.
Arasaratnam M; Gurney H
Future Oncol; 2018 Jul; 14(17):1679-1689. PubMed ID: 29460635
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
Ornstein MC; Rini BI
Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma.
Farolfi A; Schepisi G; Conteduca V; Burgio SL; Lolli C; De Giorgi U
Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1089-96. PubMed ID: 27450183
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab in renal cell carcinoma.
Michel Ortega RM; Drabkin HA
Expert Opin Biol Ther; 2015 Jul; 15(7):1049-60. PubMed ID: 26038957
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.
Joseph RW; Chatta G; Vaishampayan U
Urol Oncol; 2017 Apr; 35(4):142-148. PubMed ID: 28259541
[TBL] [Abstract][Full Text] [Related]
6. Check point inhibitors a new era in renal cell carcinoma treatment.
Alsharedi M; Katz H
Med Oncol; 2018 May; 35(6):85. PubMed ID: 29728867
[TBL] [Abstract][Full Text] [Related]
7. Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report.
Noguchi G; Tsutsumi S; Yasui M; Ohtake S; Umemoto S; Nakaigawa N; Yao M; Kishida T
BMC Urol; 2018 Apr; 18(1):26. PubMed ID: 29669553
[TBL] [Abstract][Full Text] [Related]
8. Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: On-label but without evidence.
Adrianzen Herrera DA; Fleisig SB; Gartrell BA
Invest New Drugs; 2017 Oct; 35(5):665-668. PubMed ID: 28466375
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
Zarrabi K; Wu S
Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy.
Venur VA; Joshi M; Nepple KG; Zakharia Y
Drug Des Devel Ther; 2017; 11():1175-1182. PubMed ID: 28442891
[TBL] [Abstract][Full Text] [Related]
11. Successful Therapy with Nivolumab in Metastatic Renal Cell Carcinoma After Multiple Prior Treatments.
Finelli NC; Baig SA; Masters GA
Del Med J; 2017 Jan; 89(1):14-17. PubMed ID: 29714832
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Therapy in Renal Cell Carcinoma.
Lee CH; Motzer RJ
Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903
[TBL] [Abstract][Full Text] [Related]
13. [Metastatic renal cell carcinoma, back to the future].
Martins F; Berthold D
Rev Med Suisse; 2016 May; 12(519):994-8. PubMed ID: 27424427
[TBL] [Abstract][Full Text] [Related]
14. Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC).
Atkins MB; Philips GK
Expert Opin Emerg Drugs; 2016 Sep; 21(3):243-54. PubMed ID: 27539246
[TBL] [Abstract][Full Text] [Related]
15. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers to predict prognosis and response to checkpoint inhibitors.
Yuasa T; Masuda H; Yamamoto S; Numao N; Yonese J
Int J Clin Oncol; 2017 Aug; 22(4):629-634. PubMed ID: 28382562
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
Flippot R; Escudier B; Albiges L
Drugs; 2018 Sep; 78(14):1443-1457. PubMed ID: 30187355
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
19. [Initial Clinical Experience of Nivolumab for Metastatic Renal Cell Carcinoma].
Fukunaga A; Yamasaki T; Okuno T; Imai K; Ikeuchi R; Hishiki K; Goto T; Sawada A; Negoro H; Akamatsu S; Saito R; Kobayashi T; Inoue T; Ogawa O
Hinyokika Kiyo; 2018 Oct; 64(10):383-389. PubMed ID: 30543735
[TBL] [Abstract][Full Text] [Related]
20. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
Buti S; Bersanelli M
Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
[No Abstract] [Full Text] [Related]
[Next] [New Search]
